Cargando…

Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy

Background: Current treatments of unresectable hepatocellular carcinoma (HCC) are trans-arterial chemo-embolization (TACE), stereotactic body radiotherapy (SBRT), and targeted therapy. However, these treatments are limited in efficacy and safety for patients with large tumor sizes. Here, we report a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiang, Chi-Leung, Chan, Albert C. Y., Chiu, Keith W. H., Kong, Feng-Ming (Spring)
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874138/ https://www.ncbi.nlm.nih.gov/pubmed/31799176 http://dx.doi.org/10.3389/fonc.2019.01157

Ejemplares similares

Combined Stereotactic Body Radiotherapy and Immunotherapy Versus Transarterial Chemoembolization in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Chiang, Chi-Leung, et al.
Publicado: (2021)

Comparison of clinical outcome between stereotactic body radiotherapy and radiofrequency ablation for unresectable hepatocellular carcinoma
por: Ji, Ren, et al.
Publicado: (2022)

Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study)
por: Brunner, Thomas B., et al.
Publicado: (2021)

Dosiomics and radiomics to predict pneumonitis after thoracic stereotactic body radiotherapy and immune checkpoint inhibition
por: Kraus, Kim Melanie, et al.
Publicado: (2023)

Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma
por: Yamashita, Hideomi, et al.
Publicado: (2015)

Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial
por: Li, Jian-Xu, et al.
Publicado: (2022)

Outcomes of stereotactic body radiotherapy for unresectable primary or recurrent cholangiocarcinoma
por: Jung, Da Hoon, et al.
Publicado: (2014)

Stereotactic Body Radiotherapy for the Treatment of Renal Tumors()
por: Hanzly, Michael, et al.
Publicado: (2014)

Editorial: Stereotactic body radiotherapy for prostate cancer
por: Kishan, Amar U., et al.
Publicado: (2022)

Editorial: Stereotactic body radiotherapy for lung cancer
por: Liu, An, et al.
Publicado: (2023)

Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-Analysis
por: Pan, Yang-Xun, et al.
Publicado: (2020)

Commentary: Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-Analysis
por: Li, Zhaonan, et al.
Publicado: (2021)

Editorial: Novel Applications of Stereotactic Body Radiotherapy (SBRT)
por: Kotecha, Rupesh, et al.
Publicado: (2021)

Re-Irradiation With Stereotactic Body Radiotherapy for In-Field Recurrence of Pancreatic Cancer After Prior Stereotactic Body Radiotherapy: Analysis of 24 Consecutive Cases
por: Shen, Yuxin, et al.
Publicado: (2021)

Spine Stereotactic Body Radiotherapy Outcomes in Patients with Concurrent Brain Metastases
por: Colaco, Rovel J, et al.
Publicado: (2016)

Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview
por: Zeng, Kang Liang, et al.
Publicado: (2019)

Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer
por: Weykamp, Fabian, et al.
Publicado: (2020)

Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer
por: Pepin, Abigail N., et al.
Publicado: (2022)

Feasibility, safety, and efficacy of circumferential spine stereotactic body radiotherapy
por: Dibs, Khaled, et al.
Publicado: (2022)

Combining stereotactic body radiotherapy with immunotherapy in stage IV non-small cell lung cancer
por: Liu, Xiaoli, et al.
Publicado: (2023)

Utility of Radiomics for Predicting Patient Survival in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Treated With Stereotactic Body Radiotherapy
por: Wu, Kui, et al.
Publicado: (2020)

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
por: Sun, Liwei, et al.
Publicado: (2022)

Editorial: Clinical Application of Stereotactic Body Radiotherapy (SBRT): Cranium to Prostate
por: Vargo, John A., et al.
Publicado: (2015)

Spine Stereotactic Body Radiotherapy to Three or More Contiguous Vertebral Levels
por: Dibs, Khaled, et al.
Publicado: (2022)

Stereotactic Body Radiotherapy as an Effective Treatment for Pancreatic Cancer
por: Hurmuz, Pervin, et al.
Publicado: (2023)

Stereotactic Ablative Radiotherapy Fractionation for Hepatocellular Carcinoma in the United States
por: Sheth, Niki, et al.
Publicado: (2020)

Radiation-induced organizing pneumonia after stereotactic body radiotherapy for lung tumor
por: Ochiai, Satoru, et al.
Publicado: (2015)

Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer
por: Wujanto, Caryn, et al.
Publicado: (2019)

Bibliometric Analysis of the Top-Cited Publications and Research Trends for Stereotactic Body Radiotherapy
por: Liu, Yanhao, et al.
Publicado: (2021)

Stereotactic Body Radiotherapy for Hepatocellular Carcinoma Resulting in a Durable Relapse-Free Survival: A Case Report
por: Francis, Samual, et al.
Publicado: (2016)

Consolidatory ablative stereotactic body radiation therapy after induction chemotherapy for unresectable pancreatic cancer: A single center experience
por: Lee, Hye In, et al.
Publicado: (2022)

Clinical Values and Markers of Radiation-Induced Liver Disease for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Treated With Stereotactic Body Radiotherapy
por: Jia, Jun, et al.
Publicado: (2021)

Multiple Primary Lung Cancers: Treatment Outcomes After Stereotactic Body Radiotherapy (SBRT)
por: Choi, Gyujae, et al.
Publicado: (2023)

Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol
por: Spindler, Nicklas Juel, et al.
Publicado: (2023)

Combined radiotherapy and immune checkpoint inhibition for the treatment of advanced hepatocellular carcinoma
por: Shannon, Alexander H., et al.
Publicado: (2023)

Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
por: Helbig, Doris, et al.
Publicado: (2022)

Thymic Carcinoma Treated by CyberKnife Stereotactic Body Radiotherapy
por: Harada, Yuko, et al.
Publicado: (2017)

The Early Result of Whole Pelvic Radiotherapy and Stereotactic Body Radiotherapy Boost for High-Risk Localized Prostate Cancer
por: Lin, Yu-Wei, et al.
Publicado: (2014)

A human-in-the-loop based Bayesian network approach to improve imbalanced radiation outcomes prediction for hepatocellular cancer patients with stereotactic body radiotherapy
por: Luo, Yi, et al.
Publicado: (2022)

Protocol for the STRONG trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma, a phase I feasibility study
por: Koedijk, Merel S, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vj10500m0d5taitgv96ro0vbel